| Ytd | -48.03% | |
| 1y | -39.52% |
| Open | 3.09 | Prev Close | 3.10 | Low | 2.96 | High | 3.12 | Mkt Cap | 782.31M |
| Vol | 3.63M | Avg Vol | 4.57M | EPS | -0.23 | P/E | N/A | Forward P/E | 15.44 |
| Beta | 0.73 | Short Ratio | 8.72 | Inst. Own | 73.33% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-03 | 50-d Avg | 3.44 | 200-d Avg | 5.35 | 1yr Est | 12.90 |
ARDX News
New York, New York--(Newsfile Corp. - October 30, 2026) - WHY: Rosen Law Firm, a global investor rig
Ardelyx, Inc. maintains a Hold rating as revenue growth slows and reimbursement headwinds persist, d
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suff
New York, New York--(Newsfile Corp. - October 29, 2026) - WHY: Rosen Law Firm, a global investor rig
New York, New York--(Newsfile Corp. - October 29, 2026) - Kaplan Fox & Kilsheimer LLP announces that
New class action for Ardelyx, Inc. (ARDX) urges investors to seek recovery for alleged securities fr
Alert: Claims focus on alleged misrepresentations about payer utilization management and prescriptio
NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been
Ardelyx, Inc. faces allegations that it misled investors regarding the true state of the performance
New York, New York--(Newsfile Corp. - October 28, 2026) - WHY: Rosen Law Firm, a global investor rig
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suff
NEW YORK, Oct. 28, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm,
Wall Street Reassessment: analysts repeatedly pressed Ardelyx on payer access and prior authorizatio
New York, New York--(Newsfile Corp. - October 27, 2026) - WHY: Rosen Law Firm, a global investor rig
NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suff
Ardelyx's Chief Commercial Officer, Eric Foster, is named as an individual defendant in a securities
LOS ANGELES, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shar
LOS ANGELES, Oct. 27, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm notifies investors in Ardelyx, I
New York, New York--(Newsfile Corp. - October 26, 2026) - WHY: Rosen Law Firm, a global investor rig
NEW YORK, Oct. 26, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, remi
San Diego, California--(Newsfile Corp. - October 26, 2026) - Shareholder rights law firm Robbins LLP
Ardelyx's chief executive, two successive chief financial officers, and its chief commercial officer
New class action for Ardelyx, Inc. (ARDX) urges investors to seek recovery for alleged securities fr
New York, New York--(Newsfile Corp. - October 26, 2026) - Kaplan Fox & Kilsheimer LLP announces that
LOS ANGELES, Oct. 26, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national sharehol
NEW YORK, Oct. 25, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm,
New York, New York--(Newsfile Corp. - October 25, 2026) - WHY: Rosen Law Firm, a global investor rig
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suff
New York, New York--(Newsfile Corp. - October 23, 2026) - WHY: Rosen Law Firm, a global investor rig
New York, New York--(Newsfile Corp. - October 23, 2026) - Kaplan Fox & Kilsheimer LLP announces that
Real-world analysis showed serum phosphate reductions following XPHOZAH initiation across all phosph
Real-world analysis showed serum phosphate reductions following XPHOZAH initiation across all phosph
LOS ANGELES, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shar
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suff
Ardelyx, Inc. (NASDAQ:ARDX), a commercial-stage biopharmaceutical company focused on the development
Ardelyx (NASDAQ:ARDX) released second-quarter financial results and hosted an earnings call on Thurs
Piper Sandler analyst Christopher Raymond maintains Ardelyx (NASDAQ:ARDX) with a Overweight and l
Citigroup analyst Yigal Nochomovitz maintains Ardelyx (NASDAQ:ARDX) with a Buy and lowers the pri
TD Cowen analyst Joseph Thome maintains Ardelyx (NASDAQ:ARDX) with a Buy and lowers the price tar
BTIG analyst Julian Harrison maintains Ardelyx (NASDAQ:ARDX) with a Buy and lowers the price targ
Gainers Doximity (NYSE:DOCS) stock rose 85.1% to $38.25 during Friday's pre-market session. The
US stock futures mixed, Nasdaq 100 futures up 100 points. Trade Desk Inc shares down 27.7% after wea
Atlassian Corp (NASDAQ: TEAM) reported strong Q4 results, beating revenue and earnings estimates. St
Gainers Doximity (NYSE:DOCS) stock increased by 65.6% to $34.22 during Thursday's after-market
Ardelyx (NASDAQ:ARDX) reported quarterly losses of $(0.07) per share which missed the analyst consen
Ladenburg Thalmann analyst Caroline Palomeque assumes Ardelyx (NASDAQ:ARDX) with a Buy rating and
XPHOZAH is the first and only phosphate absorption inhibitor (PAI) approved by the U.S. Food and Dru
Ardelyx (NASDAQ:ARDX) reported quarterly losses of $(0.15) per share which missed the analyst consen
